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I M M U N O L O G Y
Prostaglandin E2 promotes intestinal inflammation via 
inhibiting microbiota-dependent regulatory T cells
Siobhan Crittenden1*, Marie Goepp1*, Jolinda Pollock2, Calum T. Robb1, Danielle J. Smyth3, 
You Zhou4, Robert Andrews4, Victoria Tyrrell4, Konstantinos Gkikas5, Alexander Adima1,  
Richard A. O’Connor1, Luke Davies4, Xue-Feng Li6, Hatti X. Yao1, Gwo-Tzer Ho1, Xiaozhong Zheng1, 
Amil Mair1, Sonja Vermeren1, Bin-Zhi Qian6, Damian J. Mole1, Konstantinos Gerasimidis5,  
Jürgen K. J. Schwarze1, Richard M. Breyer7, Mark J. Arends8, Valerie B. O’Donnell4, 
John P. Iredale9, Stephen M. Anderton1, Shuh Narumiya10, Rick M. Maizels3, Adriano G. Rossi1,  
Sarah E. Howie1, Chengcan Yao1†
The gut microbiota fundamentally regulates intestinal homeostasis and disease partially through mechanisms 
that involve modulation of regulatory T cells (Tregs), yet how the microbiota-Treg cross-talk is physiologically 
controlled is incompletely defined. Here, we report that prostaglandin E2 (PGE2), a well-known mediator of 
inflammation, inhibits mucosal Tregs in a manner depending on the gut microbiota. PGE2 through its receptor EP4 
diminishes Treg-favorable commensal microbiota. Transfer of the gut microbiota that was modified by PGE2-EP4 
signaling modulates mucosal Treg responses and exacerbates intestinal inflammation. Mechanistically, PGE2-modified 
microbiota regulates intestinal mononuclear phagocytes and type I interferon signaling. Depletion of mono-
nuclear phagocytes or deficiency of type I interferon receptor diminishes PGE2-dependent Treg inhibition. Together, 
our findings provide emergent evidence that PGE2-mediated disruption of microbiota-Treg communication 
fosters intestinal inflammation.
INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic inflammatory disor-
der of the intestine that causes abdominal pain, diarrhea, bleeding, 
and increased risk of intestinal cancer. There are two main subtypes 
of IBD, i.e., Crohn’s disease (CD) and ulcerative colitis. Multiple 
factors including lifestyle (e.g., smoking, diet, medication, and 
psychological state), environmental risk factors (e.g., infections and 
air pollution), genetic and epigenetic alterations, and host immune 
functions can potentially trigger the development and progression 
of IBD (1–2). The gut microbiota plays a critical role in maintaining 
health of the host. Dysfunction of this symbiosis may result in de-
velopment of various human diseases such as IBD, metabolic syn-
drome, infections, allergy, and cancer (3–4). Interplay between the 
host and gut microbiota controls intestinal homeostasis and inflam-
matory responses through mechanisms that involve modulation of 
gut-resident regulatory T cells (Tregs), which express the transcrip-
tion factor, forkhead box P3 (Foxp3) (5–8). Dysregulation of intes-
tinal Tregs is implicated in the pathogenesis of IBD (9). Microbial 
antigens, metabolites [e.g., vitamins and short-chain fatty acids 
(SCFAs)], and signaling molecules released during tissue damage 
(e.g., alarmins) contribute to the induction of distinct intestinal Treg 
subsets, which play critical roles in intestinal homeostasis and con-
trol mucosal inflammation (10–13). However, the mechanisms that 
negatively regulate microbiota-Treg cross-talk for IBD pathogenesis 
are incompletely studied.
Prostaglandins (PGs) are bioactive lipid mediators that are gen-
erated from arachidonic acid via cyclooxygenases (COXs) and spe-
cific PG synthases (14). The PG family has five members including 
PGE2, PGD2, PGF2, PGI2, and thromboxane A2 (TXA2). PGs signal 
in an autocrine and/or paracrine manner through their distinct 
G protein–coupled receptors including receptors EP1 to EP4, 
PGD2 receptors DP1 and DP2, PGF2 receptor FP, PGI2 receptor IP, 
and TXA2 receptor TP. PGE2 is present in most tissues at biologically 
functional nanomolar levels in the steady state, and its levels are 
increased at the sites of inflammation (14–16). Nonsteroidal anti- 
inflammatory drugs (NSAIDs), such as aspirin and indomethacin, 
are widely used to reduce pain, fever, and inflammation by inhibiting 
COX activities and therefore decreasing PG production. However, 
NSAIDs are generally avoided for individuals who have gut condi-
tions due to the gastrointestinal adverse effects (17). This is because 
PGE2 plays critical roles in maintaining the gut epithelium, protecting 
against acute damage, and facilitating regeneration after injury 
through actions on various cell types including macrophages, epi-
thelial, stromal, and innate lymphoid cells (18–21).
Genome-wide association studies have revealed that polymor-
phisms in the PTGER4 gene (encoding human PGE2 receptor EP4) 
are associated with overexpression of EP4 and a more severe disease 
phenotype in patients with IBD (22–24). Moreover, variants in the 
PTGER4 gene exert a significant association with CD, in third place 
among all susceptible genetic loci after variants in NOD2 and IL23R 
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genes (25). These findings raised a possibility that PGE2-EP4 signal-
ing may also participate in the pathogenesis of intestinal inflamma-
tion despite its protective actions on the epithelium. We and others 
have recently found that PGE2 plays key roles in immune-related 
chronic inflammatory diseases in rodents and humans, for exam-
ple, multiple sclerosis, rheumatoid arthritis, and inflammatory skin 
disorders, through promoting interferon- (IFN-)–producing T 
helper 1 (TH1) cells and interleukin-17 (IL-17)–producing TH17 cells 
by induction of key cytokine receptors IL-12R2 and IL-23R, re-
spectively (26–29). However, the action of PGE2 on Treg responses, 
especially in the intestine, remains unknown. In this study, we in-
vestigated the roles for endogenous PGE2 in regulation of mucosal 
Treg responses and intestinal inflammation. We demonstrate that 
PGE2 down-regulates intestinal Treg responses by affecting the com-
position of the gut microbiota and modulating the function of 
mononuclear phagocytes (MNPs).
RESULTS
Production of PGs and expression of their receptors 
in the intestine
First, we examined whether the intestine tissues physiologically 
produce PGs and whether inhibition of COXs reduces PG levels in 
the steady state. We administered naïve wild-type (WT) C56BL/6 
mice with a nonselective COX inhibitor, indomethacin, at the dose 
of 5 mg/kg per day (equaling to ~30 mg/day for an adult human 
weighing 75 kg) or vehicle control [0.5% ethanol (EtOH)] in drink-
ing water. Intestine tissues were collected on day 5 for measuring 
levels of PGs by lipidomic analysis. We observed that healthy small 
and large intestines in control mice produced high levels (i.e., hun-
dreds to thousands nanogram per gram dry tissue) of PGs including 
PGE2, PGD2, PGF2, TXA2 metabolite (i.e., TXB2), and PGI2 metab-
olite (i.e., 6-keto PGF1) (Fig. 1A and fig. S1). Small intestine pro-
duced more PGD2 and TXB2, but less PGF2 and 6-keto PGF1, than 
the colon, while both intestinal tissues had comparable levels of 
PGE2 and its metabolite (13,14-dihydro-15-keto PGE2) or epimer 
(8-iso PGE2) (Fig. 1A). Administration of indomethacin nearly com-
pletely inhibited production of all PGs (e.g., PGE2, PGD2, and 
PGF2) and their inactive metabolites, i.e., 15-keto PGE2, 15-keto 
PGD2, 15-keto PGF2, 6-keto-PGF1, and TXB2 in both small and 
large intestines (Fig. 1A). For example, indomethacin reduced PGE2 
levels by ~96% (from 2628 to 105 ng/g of dry tissue) in small intes-
tines and by ~99% (from 2789 to 29 ng/g of dry tissue) in colons 
(Fig. 1A). Reanalysis of public datasets (30) revealed that both mouse 
and human intestines express EP4 genes (i.e., Ptger4 and PTGER4, 
respectively) at the levels remarkedly higher than other PG recep-
tors (Fig. 1, B and C), indicating that the PGE2-EP4 pathway may 
play a more important role than other PG signaling in the intestine.
Increase of intestinal Tregs by COX inhibition
To test whether endogenous PGs regulate intestinal Tregs in the 
steady state, we administered WT mice with indomethacin in drink-
ing water and analyzed Tregs in various organs including colons, 
small intestines, mesenteric lymph nodes (mLNs), and spleens. In-
domethacin treatment increased the accumulation of Foxp3+ Tregs 
in all of these tissues with greater effects in the intestinal lamina 
propria (LP) (by ~2-fold in the colon and small intestine) than that 
in the mLN and spleen (both by ~1.4-fold) (Fig. 2, A and B). Fur-
thermore, indomethacin significantly increased mean fluorescence 
intensity (MFI) of Foxp3 among Foxp3+ Tregs in the colon (Fig. 2B), 
suggesting that inhibition of endogenous PG biosynthesis not only 
increases intestinal Treg frequencies but also enhances Foxp3 ex-
pression at the single-cell level. We also administered mice with in-
domethacin at lower doses of 1 to 2 mg/kg of body weight per day, 
which is the equivalent of ~6 to 12 mg/day for adults weighing 
75 kg, levels known not to induce intestinal damage in human. Sim-
ilarly, low doses of indomethacin still increased intestinal Foxp3+ 
Tregs (fig. S2).
It has been recently reported that a subpopulation of intestinal 
Tregs that express the transcription factor retinoid-related orphan 
receptor gamma t (RORt), namely, RORt+Foxp3+ Tregs, inhibit 
intestinal inflammation with greater suppressive potential than 
RORt−Foxp3+ Tregs (6, 7, 31). We therefore examined the effects of 
endogenous PGs on RORt+Foxp3+ Tregs and found that adminis-
tration of indomethacin markedly increased the percentages of the 
RORt+Foxp3+ subpopulation among Foxp3+ Tregs in the colon, but 
not in the mLN or spleen (Fig.  2,  C  and  D). Furthermore, indo-
methacin also boosted absolute numbers of colonic RORt+Foxp3+ 
Tregs, but not the numbers of RORt−Foxp3+ Tregs or RORt+Foxp3− 
TH17 cells (Fig. 2E). These results indicate that inhibition of endog-
enous PGs increases the accumulation of intestinal Tregs.
Reversion of COX inhibition–dependent increase 
in intestinal Tregs by EP4 agonism
As indomethacin inhibits all PG production, we next examined 
whether PGE2 and its receptors control intestinal Tregs. We co-
administered mice with indomethacin together with a selective EP2 
agonist (Butaprost) or selective EP4 agonists (L-902,688). We found 
that increase in colonic Tregs by indomethacin was prevented by the 
EP4 agonist in colons and mLNs, while the EP2 agonist only 
reduced Tregs in mLNs (Fig. 2, A and B), indicating that PGE2 sup-
presses colonic Treg accumulation mainly through EP4. Similarly, co-
administration of EP4 agonist notably down-regulated RORt+Foxp3+ 
Tregs in the colon and likely in the small intestine, but not in the 
mLN or spleen (Fig. 2, C and D). Furthermore, selective activation 
of EP4 also decreased absolute numbers of colonic RORt+Foxp3+ 
Tregs, but not RORt−Foxp3+ Tregs or RORt+Foxp3− TH17 cells 
(Fig. 2E). These results indicate that activation of PGE2-EP4 signal-
ing overturns NSAID-dependent augmentation of Tregs with the 
greatest potency in the intestine.
To further examine whether exogenous activation of EP4 sup-
presses colonic Tregs, we injected the EP4 agonist alone into naïve 
WT C57BL/6 mice without coadministration of indomethacin. 
Unlike activation of EP4 in indomethacin-treated mice where all en-
dogenous PG production was inhibited (Fig. 2), administration of 
EP4 agonist into naïve WT mice where all PG signaling pathways 
were intact had few effects on colonic Treg accumulation, albeit a 
trend for reducing the proportion of RORt+Helio− Tregs (fig. S3). 
This may be due to the already high levels of PGE2 and other EP4 
ligands (e.g., PGE1) in naïve intestines (Fig. 1A). There is another 
possibility that blockade of endogenous PGs by indomethacin dis-
rupted the intestinal epithelial line (19), which leads to attachment 
and translocation of more invasive commensal microbes and in 
turn increases the accumulation of colonic Tregs. Coadministration 
of EP4 agonist prevented indomethacin-dependent epithelial dam-
age and attachment of invasive microbes, resulting in reduction of 
colonic Treg accumulation. In the naïve intestine without disruption 
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EP4 agonism has thus no influence on Treg accumulation in the co-
lon. Nevertheless, these results collectively indicate that PGE2-EP4 
signaling has a potency to inhibit intestinal Treg accumulation.
Involvement of the gut microbiota in PGE2 suppression 
of intestinal Tregs
To examine whether PGE2-EP4 signaling inhibits intestinal Tregs in 
the steady state via direct or indirect actions on T cells, we generated 
Lck-Cre–driven EP4 conditional knockout mice by crossing EP4-
flox mice (32) to Lck-Cre mice (i.e., LckCreEP4fl/fl mice) to delete 
EP4 expression in Lck-expressing T cells. LckCreEP4fl/fl and control 
mice had comparable colonic Treg accumulation in the steady state 
(Fig. 3, A and B), suggesting that PGE2 inhibits intestinal Treg accu-
mulation in the steady state independent of EP4 signaling in T cells.
The gut microbiota is crucial for the development of intestinal 
Tregs, especially the RORt+Foxp3+ Treg subset (6, 7, 31). We therefore 
investigated whether the gut microbiota is involved in PGE2-dependent 
control of intestinal Tregs. We analyzed colonic Tregs from WT mice 
Fig. 1. Expression of PGs and their receptors in the intestine. (A) Levels of PGs and their metabolites in small intestines and colons from mice administered with indo-
methacin or vehicle control in drinking water for 5 days (n = 6 each group) as measured by lipidomic analysis. (B) Gene expression of PG receptors in mouse small and 
large intestines. Microarray gene expression data of normal C57BL/6 mouse colons (n = 3) were retrieved from the Gene Expression Omnibus (GEO) dataset GSE31106. 
RNA sequencing (RNA-seq) data of normal C57BL/6 mouse small intestines (n = 3) were retrieved from the GEO dataset GSE97371. (C) Gene expression of PG receptors in 
human sigmoid (n = 149) and transverse (n = 104) colon biopsy samples of healthy individuals. RNA-seq data were downloaded from the Genotype-Tissue Expression 
project database and analyzed using Python 3.7.0. RPKM, reads per kilobase of transcript. Each scatter dot plot in bar graphs represents data from one mouse (A and B) or 
individual (C). Data shown as means ± SD (A and B) or presented as violin bars with scatter plots (C) are analyzed by analysis of variance (ANOVA) with post hoc Holm-Sidak’s 
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in which the gut microbiota had been depleted by antibiotics, or 
from MyD88/TRIF double knockout mice deficient in both myeloid 
differentiation primary response 88 (MyD88) and TRI domain contain-
ing adaptor-inducing interferon-beta (TRIF) that were unable to sense 
microbial signals. Inhibition of endogenous PGE2 by indomethacin 
increased both the frequencies and numbers of colonic Tregs (especially 
the subpopulation of RORt+Foxp3+ Tregs) but not RORt+ Foxp3− 
TH17 cells in WT mice that have been treated with vehicle control 
(Fig. 3C). In contrast, there was no increased accumulation of colonic 
Tregs by indomethacin in antibiotic-treated WT mice nor in those mice 
with dual deficiency of MyD88 and TRIF (Fig. 3C). Similarly, acti-
vation of EP4 reduced indomethacin-dependent increase in colonic 
RORt+Foxp3+ Tregs in vehicle-treated, rather than antibiotic-treated, 
mice (Fig. 3C). These results suggest involvement of the commensal 
microbiota in the PGE2-dependent control of intestinal Tregs.
Alteration of the gut microbiota by PGE2-EP4 signaling
Use of NSAIDs has been reported to induce changes in the gut 
microbiota composition in humans and rodents (33–35). To examine 
whether PGE2-EP4 signaling modulates the gut microbiota, we collected 
Fig. 2. PGE2-EP4 signaling inhibits intestinal Tregs in the steady state. (A) Representative flow cytometry plots of Foxp3+ Tregs gated on live CD45+CD3+CD4+ T cells in 
colon and small intestinal LP, mLN, and spleen from C57BL/6 mice that were treated with vehicle (Veh) or indomethacin (Indo) in drinking water and injected intraperito-
neally with an EP2 agonist, Butaprost, or an EP4 agonist, L-902,688 (n = 8 to 12). (B) Percentages of Foxp3+ Tregs (top) and geometric MFI (gMFI) of Foxp3 (bottom). 
(C) Representative flow cytometry dot plots of RORt expression among Foxp3+ Tregs in colon and small intestinal LP. (D) Percentages of RORt expression by Foxp3+ Tregs. 
(E) Absolute numbers of RORt+Foxp3+ Tregs, RORt−Foxp3+ Tregs, RORt+Foxp3− TH17 cells in colon LP (cLP). Each scatter dot plot in bar graphs represents data from one mouse. 
Data shown as means ± SD are pooled from four independent experiments and analyzed by ANOVA with post hoc Holm-Sidak’s multiple comparisons test (B, D, and E). 
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cecal contents from mice that had been treated with indomethacin or 
that had been cotreated with indomethacin and an EP4 agonist and 
performed 16S ribosomal RNA (rRNA) gene metabarcoding to study 
microbiota composition. Principal components analysis (PCA) sug-
gested that there were no differences in overall -diversity of gut micro-
biota signatures measured by unweighted UniFrac distances among the 
three groups (Fig. 4A). The analysis of -diversity indices (i.e., richness 
and evenness) showed that the three groups had also comparable ob-
served operational taxonomic units (OTUs), Chao1 index, Shannon 
diversity, and Inverse Simpson (InvSimpson) indices (Fig. 4B). How-
ever, there were trends showing that the indomethacin+EP4 agonist–
treated group had higher observed OTUs and Chao1 index (Fig. 4B).
We then asked whether PGE2-EP4 signaling alters specific bac-
terial communities. We found that treatment with indomethacin 
increased the abundance of the Firmicutes phylum and reduced 
the abundance of the Bacteroidetes phylum, and the changes in 
phylum-level microbiota composition by indomethacin were slightly 
reversed by cotreatment with the EP4 agonist (Fig. 4C). Indomethacin 
increased, but EP4 agonist reduced, several SCFA-producing bacteria 
belonging to the Muribaculaceae family or the Clostridium cluster 
XIVa (e.g., Lachnospiraceae and Ruminococcaceae) (Fig. 4D) (5). 
SCFA-producing bacteria such as Clostridia play critical roles in in-
testinal Treg induction and accumulation. Furthermore, Anaeroplasma 
bactoclasticum, which promotes expression of immune-regulatory 
transforming growth factor– in the gut (36), was also up-regulated 
by indomethacin and reduced by the EP4 agonist (Fig. 4D). To 
validate the 16S rRNA gene sequencing results, we used real-time 
quantitative polymerase chain reaction (qPCR) to detect gene ex-
pression of SCFA-producing bacteria in mice from independent 
cohorts. As confirmed, activation of EP4 significantly reduced the 
phylum Firmicutes and increased the phylum Bacteroidetes (Fig. 4E). 
In agreement with the 16S RNA sequencing (RNA-seq) results, 
EP4 activation notably decreased the amounts of Clostridia in-
cluding total Clostridium cluster XIVa, Clostridium sp., Clostridium 
coccoides, ASF500 (Ruminococcaceae), and ASF360 (Lactobacillus sp.) 
(Fig. 4E). In addition, several aggressive microbial species such as 
species of the genera Rikenella and Escherichia were also increased 
by indomethacin but reduced by coadministration of EP4 agonist 
(Fig. 4D). Rikenella and Escherichia are pathogenic strains that can 
trigger mucosal inflammation and formation of mucus lesions (37). 
Therefore, besides SCFA-producing gut microbes, these patho-
genic bacteria may also contribute to NSAID/PGE2-dependent 
Fig. 3. The gut microbiota is involved in PGE2-EP4 signaling regulation of intestinal Tregs. (A and B) Representative flow cytometry plots (A) and percentages and 
numbers (B) of RORt+Foxp3+ Tregs, RORt−Foxp3+ Tregs, RORt+Foxp3− TH17 cells in colon LP of LckCreEP4fl/fl (n = 5) and control (n = 4) mice determined by flow cytometry. 
(C) Percentages and numbers of RORt+Foxp3+ Tregs, RORt−Foxp3+ Tregs, and RORt+Foxp3− TH17 cells in colon LP of WT and MyD88/TRIF double knockout (DKO) mice 
that were treated with vehicle, indomethacin, or indomethacin plus EP4 agonist, L-902,688 (n = 7 to 18). Antibiotics (ABX) were administered to WT mice in drinking water 
for 2 weeks started 1 week before receiving indomethacin or vehicle. Each scatter dot plot in bar graphs represents data from one mouse. Data shown as means ± SD are 
pooled from two (B) or five (C) experiments and analyzed by ANOVA with post hoc Holm-Sidak’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, and 
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Fig. 4. PGE2-EP4 signaling alters the gut microbiota. (A to D) DNA extracts of the cecal contents from C57BL/6 mice receiving vehicle control or indomethacin plus EP4 
agonist for 5 days (n = 8 per group) were analyzed by 16S rRNA gene sequencing. (A) PCoA of cecal microbiota structure as measured by unweighted UniFrac distances 
among the three groups. (B) -Diversity of the gut microbiome as measured by observed OTUs, Chao1 index, Shannon diversity, and InvSimpson index. (C) Phylum-level 
microbiota composition expressed as relative abundances. (D) Bacterial species changed in relative abundance among different groups. (E) 16S rRNA gene expression of 
indicated commensal microbiota in cecal contents obtained from C57BL/6 mice treated with vehicle (n = 17), indomethacin (n = 18), or indomethacin plus EP4 agonist 
L-902,688 (n = 9) for 5 days. Relative abundance of each group of bacteria to total cecal bacteria was determined by real-time quantitative polymerase chain reaction 
(qPCR) and normalized to the vehicle group. (F) Relative SCFA levels in cecal contents from mice treated with vehicle (n = 22), indomethacin (n = 22), or indomethacin plus 
EP4 agonist L-902,688 (n = 18). Amounts of SCFAs were detected using gas chromatography and normalized to the vehicle group. Each scatter dot plot represents data 
from one mouse (A, B, and D to F). Data plotted in box and whiskers bar graphs are pooled from five experiments and analyzed by nonparametric Kruskal-Wallis test with 
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modulation of gut epithelial injury and accumulation of Tregs in the 
intestine.
To examine whether PGE2 modulates SCFA production, we 
measured SCFA levels in cecal contents. Indomethacin treatment 
significantly increased the levels of caproic acids and branched 
SCFAs (isobutyric and isovaleric acids) in extracts of cecal contents 
(Fig. 4F). Indomethacin also had a trend to enhance valeric acid 
(Fig. 4F). Coadministration of EP4 agonist specifically reduced 
the levels of caproic acid (Fig. 4F). The levels of caproic and valeric 
acids were found significantly decreased in feces from patients with 
active CD compared to inactive CD or healthy controls (38, 39). 
Clostridia are producers of caproic acid and branched SCFAs in-
cluding isobutyric and isovaleric acids (40, 41). Branched SCFAs, 
similar to conventional SCFAs modulate the host immune response 
(42). These corroboratory results thus suggest that PGE2-EP4 
signaling reduces intestinal Treg accumulation, at least partially, via 
reducing SCFA-producing microbiota.
Modulation of mucosal Tregs and intestinal inflammation by 
EP4-modified gut microbiota
To investigate whether PGE2-modified microbiota modulates intes-
tinal Treg responses and inflammation, we adoptively transferred 
cecal microbiota obtained from WT C57BL/6 mice that had been 
treated with indomethacin, indomethacin plus EP4 agonist, or 
vehicle control into recipient WT C57BL/6 mice (Fig. 5A). Recipient 
mice were pretreated with antibiotics in drinking water for 2 weeks 
before receiving transplantation of microbiota and then received 
normal drinking water for another 10 days, followed by euthanasia 
to analyze colonic immune cell responses at the steady state. Some 
recipient mice received normal drinking water for 8 days after 
stopping antibiotic treatment, followed by receiving dextran 
sulfate sodium (DSS) in drinking water for an additional 6 days 
(Fig. 5A). Compared to mice that had received cecal microbiota from 
vehicle-treated mice, mice transplanted with cecal microbiota from 
indomethacin-treated mice had increased Tregs and Foxp3 expression 
at single-cell levels in the steady state (Fig. 5B). This increased expres-
sion was associated with prevention of body weight loss, reduced 
disease activity index (DAI), and increased colon length under DSS- 
induced inflammatory conditions in mice that had received cecal mi-
crobiota from indomethacin- treated mice (Fig. 5, C and D). In con-
trast, mice transplanted with cecal microbiota from mice that have 
been pretreated with indomethacin plus EP4 agonist had a trend to 
reduce colon Tregs and Foxp3 expression compared to mice received 
cecal microbiota from mice that have been pretreated with indo-
methacin (Fig. 5B). Furthermore, the severity of colitis in mice trans-
planted with cecal microbiota from mice that have been pretreated 
with both indomethacin and EP4 agonist was similar to mice that had 
received cecal microbiota from vehicle-treated mice but was significantly 
greater than that in mice received cecal microbiota from indomethacin- 
treated mice (Fig. 5, C to E). Histological analysis showed near normal 
proximal and distal colonic mucosa, or only scattered mild inflam-
matory changes, in mice transplanted with cecal microbiota from 
indomethacin-treated mice (Fig. 5F). There was widespread and 
variably severe mucosal ulceration with patches of almost complete 
loss of the crypt epithelium, with marked infiltration of fibrotic mu-
cosal tissue by both acute and chronic inflammatory cells in mice 
that had received cecal microbiota from vehicle-treated mice, with 
more severe inflammatory and ulcerative changes in the distal co-
lon compared with the proximal colon. In contrast, there was a less 
severe pattern of inflammation with more variable mild to moder-
ate inflammatory cell infiltration with only patchy partial loss of 
mucosal crypt epithelium in those mice transplanted with cecal mi-
crobiota from indomethacin- and EP4 agonist–treated mice, again 
with greater inflammatory changes in the distal colon compared 
with the proximal colon (Fig. 5F). This was associated with reduced 
T cell infiltration to colon LP in mice that have received cecal mi-
crobiota from indomethacin-treated mice compared to the other 
two groups (Fig. 5G). Together, these results suggest that PGE2-EP4 
signaling–modified gut microbiota contributes to inhibition of mu-
cosal Tregs and exacerbation of intestinal inflammation.
Increased colonic Treg accumulation in MNP-specific 
EP4-deficient mice
MNPs are critical to mediate the microbiota-dependent generation 
of intestinal Foxp3+ Tregs (43–45). To further study the interplay 
between PGE2 and the gut microbiota in the control of intestinal 
Tregs, we examined MNPs in the colon. Comparing to treatment 
with vehicle control, administration of indomethacin increased both 
the frequency and number of colonic CD11c+MHC II+CD11b+ MNPs, 
and this was again inverted by coadministration of the EP4 agonist 
(Fig. 6A). CD11c+MHC II+CD11b− MNPs were not affected by ei-
ther indomethacin or EP4 activation (Fig. 6A). The effects of indo-
methacin and EP4 agonist on colonic CD11c+MHC II+CD11b+ 
MNPs were invisible in colons of antibiotic-treated mice or in 
MyD88/TRIF double-deficient mice (Fig. 6A). Moreover, transfer 
of gut microbiota from mice that had been treated with indometha-
cin increased colonic CD11c+MHC II+CD11b+ MNPs in host mice, 
and this was again reduced by transfer of gut microbiota from mice 
that had been cotreated with indomethacin and EP4 agonist (Fig. 6B). 
These results indicate that PGE2-EP4 signaling suppresses intestinal 
MNPs through modulating the gut microbiota.
Next, we asked whether CD11c+MHC II+CD11b+ MNPs medi-
ate PGE2 suppression of intestinal Tregs. To address this, we took 
advantage of mice that have CD11b promoter–driven expression of 
the human diphtheria toxin (DT) receptor (CD11b-DTR mice). In-
jection of DT selectively depleted colonic LP CD11c+MHC II+CD11b+ 
MNPs (by ~90%), rather than CD11c+MHC II+CD11b− MNPs, and 
markedly reduced CD11b expression at the single-cell level in co-
lonic CD11c+MHC II+CD11b+ MNPs (Fig. 6, C and D). While in-
domethacin increased and EP4 agonist decreased colonic Foxp3+ 
Tregs in phosphate-buffered saline (PBS)–treated CD11b-DTR mice, 
respectively, neither indomethacin nor EP4 agonist affected colonic 
Tregs in DT-treated CD11b-DTR mice (Fig. 6E). These results sug-
gest that CD11c+MHC II+CD11b+ MNPs mediate PGE2 suppression 
of intestinal Tregs. Furthermore, the C-C chemokine receptor type 2 
(CCR2) mediates migration of monocyte-derived macrophages 
to the intestine. Mice deficient in CCR2 had reduced intestinal 
CD11c+MHC II+CD11b+ MNP numbers (by ~50%) and CD11b expres-
sion at the single-cell level compared to WT mice (fig. S4A). However, 
CCR2 deficiency did not prevent, if not enhanced, indomethacin- 
dependent increase in colonic Foxp3+ Tregs (fig. S4B), suggesting a 
role for gut resident but not monocyte-derived migratory MNPs in 
PGE2-dependent inhibition of intestinal Tregs.
We further asked whether EP4 signaling in MNPs suppresses 
colonic Tregs. To address this question, we crossed EP4-flox mice to 
CD11c-Cre mice to generate MNP-specific EP4-deficient mice. In-
activation of EP4 signaling in MNPs increased both percentages 
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Fig. 5. Altered gut microbiota by PGE2-EP4 signaling suppresses intestinal Treg responses and promotes intestinal inflammation. (A) Experimental schematic 
diagram of cecal microbiota transplantation (CMT). Recipient C57BL/6 mice were pretreated with antibiotics for 2 weeks and rest for 1 day before receiving fresh cecal 
microbiota collected from C57BL/6 mice that had been treated with vehicle (Veh-CMT), indomethacin (Indo-CMT), or indomethacin plus EP4 agonist, L-902,688 (Indo/EP4 
ago-CMT) for 5 days. After antibiotics treatment, some recipient mice were given back normal drinking water for 9 days before euthanized for analysis of colon immune 
cells [for (B)], while some other recipient mice were given back normal drinking water for 7 days, followed by administration with DSS in drinking water to induce colonic 
inflammation [for (C) to (G)]. (B) Numbers of colon LP Foxp3+ Tregs (left) and Foxp3 gMFI (right) in the recipient mice on day 9 after CMT (n = 5 to 6 each group). (C) Changes 
in body weight of recipient mice showing percentages of that at the beginning of DSS treatment (i.e., day 7). (D) DAI of the recipient mice (right) (n = 6 each group). 
(E) Representative images of the cecum and colon tissues (left) and colon lengths (right) of the recipient mice on day 13. Photo credit: Marie Goepp, University of Edinburgh. 
(F) Representative histological (hematoxylin and eosin–stained) images of distal (top row) and proximal (bottom row) colons of the recipient mice (all at same magnifica-
tion, 100×). Scale bar, 200 m. (G) Numbers of infiltrated CD3+ T cells in colon LP of the recipient mice. Each scatter dot plot in bar graphs represents data from one mouse. 
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Fig. 6. PGE2 inhibits intestinal MNPs via the gut microbiota, required for control of Tregs. (A) Percentages (top) and numbers (bottom) of colon LP CD11c+MHC 
II+CD11b+ and CD11c+MHC II+CD11b− MNPs from C57BL/6 WT and MyD88/TRIF double knockout mice treated with vehicle, indomethacin, or indomethacin plus EP4 
agonist L-902,688 (n = 7 to 18). Antibiotics were administered to WT mice in drinking water for 2 weeks started 1 week before receiving indomethacin or vehicle. (B) Percent-
ages (top) and numbers (bottom) of colon LP CD11c+MHC II+CD11b+ and CD11c+MHC II+CD11b− MNPs in mice that were treated with antibiotics for 2 weeks, followed by 
transfer of cecal microbiota harvested from mice that had been administered with vehicle (Veh-CMT), indomethacin (Indo-CMT), or indomethacin plus EP4 agonist (Indo/
EP4 ago-CMT) (n = 5 to 6). (C and D) Representative flow cytometry plots (C) and percentages (D) of colon LP CD11c+MHC II+CD11b+ and CD11c+MHC II+CD11b− MNPs at 
colon LP of CD11b-DTR mice administered with diphtheria toxin (DT) or phosphate-buffered saline (PBS) (n = 6 each group). CD11b geometric gMFI of CD11c+MHC 
II+CD11b+ MNPs are also shown (D, right). (E) Numbers of colon LP CD45+CD3+CD4+Foxp3+ Tregs in CD11b-DTR mice treated with DT or PBS together with vehicle control, 
indomethacin, or indomethacin plus EP4 agonist (n = 6 to 12). (F) Representative flow cytometry plots of colonic Foxp3+ Tregs gated on live CD45+CD3+CD4+ T cells and 
RORt+ or Helios+ Tregs in CD11cCreEP4fl/fl (n = 6) or control EP4fl/fl mice (n = 5). (G) Percentage and numbers of Foxp3+ Tregs. (H) Percentage and numbers of RORt+Helios−, 
RORt−Helios−or Helios+ Tregs. Each scatter dot plot in bar graphs represents data from one mouse. Data shown as means ± SD are pooled from five (A), three (D and E), or 
one (B, G, and H) independent experiments and analyzed by ANOVA with post hoc Holm-Sidak’s multiple comparisons test (A, B, and E) or two-tailed unpaired Student’s 
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Subsequent analysis revealed that EP4 deficiency in MNPs specifi-
cally boosted colonic RORt+Helios− Tregs and had few, if not inhib-
itory, effects on the RORt−Helios− Treg subset (Fig. 6, F and H). 
Together, these results indicate that EP4 signaling in MNPs is re-
sponsible for PGE2 inhibition of colonic RORt+ Tregs.
Impaired type I IFN signaling responsible for PGE2 
suppression of intestinal MNPs and Tregs
MNPs mediate intestinal Treg development and expansion by pro-
ducing soluble mediators such as type I IFNs (46, 47). The IFN-/ 
receptor (IFNAR) signaling pathway has been shown to be required 
for Treg development and function, especially under stress condi-
tions or in a competitive environment (48). To test whether PGE2 
regulates type I IFN signaling in intestinal CD11c+MHC II+CD11b+ 
MNPs, we cultured bone morrow–derived dendritic cells (BMDCs) 
without (medium only) or with cecal microbial products (CMPs; 
which might include pathogen- or microbe-associated molecular 
patterns including gut microbial metabolites) obtained from mice 
that had been treated with vehicle control, indomethacin, or indo-
methacin plus EP4 agonist. We then measured mRNA expression 
of type I IFN signaling pathway genes in BMDCs by real-time 
qPCR. BMDCs cultured with CMPs from control mice were char-
acterized by higher expression of type I IFN (e.g., Ifnb) and the 
downstream genes (e.g., Irf7 and Isg15) compared to that cultured 
with medium only (Fig. 7A). Expression of Irf7 and Isg15 was fur-
ther increased in BMDCs cultured with CMPs obtained from mice 
that had been treated with indomethacin compared to that cultured 
with CMPs obtained from control mice (Fig. 7A). In contrast, mRNA 
expression levels of all these genes were markedly down-regulated 
in BMDCs that had been cultured with CMPs obtained from mice 
that have been cotreated with indomethacin and EP4 agonist (Fig. 7A). 
Moreover, colonic CD11c+MHC II+ MNPs sorted from indomethacin- 
treated mice expressed higher levels of type I IFN signaling path-
way genes (e.g., Ifnb, Irf7, and Isg15) compared to MNPs sorted 
from colons of vehicle-treated mice (Fig.  7B). Colonic MNPs in 
mice treated with indomethacin had higher levels of phosphorylated 
signal transducers and activators of transcription 1 (STAT1) than 
that in vehicle-treated mice (Fig. 7C). These results suggest that 
modulation of gut microbial products by PGE2-EP4 signaling 
inhibits type I IFN production and signaling in MNPs. Similarly, 
colonic Tregs from indomethacin-treated mice also had more Tregs 
expressing phosphorylated STAT1 compared to vehicle-treated mice 
(Fig. 7D).
We next examined whether type I IFN signaling is required for 
PGE2 control of intestinal Tregs using IFNAR  chain (Ifnar)–deficient 
mice. Again, indomethacin increased colonic CD11c+MHC II+CD11b+ 
MNPs and RORt+Foxp3+ Tregs, and this was prevented by EP4 
agonist in WT mice (Fig. 7 E and F). However, neither indomethacin 
nor EP4 agonist had effects on colonic CD11c+MHC II+CD11b+ MNPs 
and RORt+Foxp3+ Tregs in Ifnar-deficient mice (Fig. 7, E and F). 
These results thus suggest that the PGE2-modified microbiota 
suppresses intestinal Tregs by down-regulating type I IFN signaling 
via MNPs.
DISCUSSION
In this report, we have demonstrated that PGE2, the well-known 
mediator of inflammation, negatively controls intestinal Treg responses. 
Endogenous PGE2-EP4 signaling alters the gut microbial community, 
e.g., reducing SCFA-producing bacteria, which in turn down-regulates 
MNP production of type I IFNs, leading to repression of intestinal 
Treg accumulation and augmentation of intestinal inflammation 
(Fig. 7G). In contrast, blockade of PGE2 signaling (e.g., by NSAIDs) 
increases beneficial microbes and also some invasive microbes, likely 
as a consequence of damage to the epithelium, which augments 
MNP production of IFNs, resulting in expansion of mucosal Tregs 
and limitation of intestinal inflammation.
There are several potential mechanisms underpinning EP4- 
dependent inhibition of intestinal Tregs as PGE2 could target 
multiple enteric cell types including epithelial cells, T cells, and 
MNPs. Mice with EP4 deficiency in T cells had comparable num-
bers of intestinal Tregs to EP4-sufficient mice, excluding a role for 
EP4 signaling in T cells. Specific deletion of EP4 in epithelial cells 
(e.g., driven by Villin-cre) impaired colon homeostasis, increased 
epithelial cell apoptosis and immune cell infiltration, and exacer-
bated DSS-induced mucosal inflammation (49). Although Treg ac-
cumulation in the colon in epithelial EP4–deficient mice has not 
been assessed, gene expression of Foxp3 that is exclusively expressed 
on Tregs in colon tissue is comparable between epithelial-specific 
EP4 deficient and control mice (49). Thus, endogenous PGE2 is un-
likely to act through epithelial cells for Treg inhibition in the naïve 
intestine. However, use of NSAID (e.g., indomethacin) may destroy 
the epithelium, leading to translocation of commensal microbes (19). 
Attachment of some invasive commensal microbes (e.g., Helicobactor 
hepaticus) to the epithelium is believed to favorably increase Treg 
accumulation in the gut (50). Specific activation of EP4 agonism 
may thus contribute to reversing NSAID-dependent increase in in-
testinal Tregs by preventing NSAID-dependent epithelial injury. 
This is, at somewhat extend, supported by the finding that EP4 
agonist alone (without indomethacin) had few effects on colonic Treg 
accumulation (fig. S3). Therefore, a possibility that indomethacin 
increases colonic Tregs, at least partly, through epithelial injury and 
attachment of the invasive microbes cannot be excluded.
Blockade of PGE2 biosynthesis by NSAIDs alters the gut micro-
biota by expanding the beneficial SCFA-producing microbes and 
increasing SCFA secretion in the intestine, which was reversed by 
the EP4 agonist. Given an increased ratio of Firmicutes to Bacteroi-
detes has been reported to be related to anti-inflammatory potential 
under various inflammatory conditions (3), our results showing 
that PGE2-EP4 signaling reduced Firmicutes but increased Bacte-
roidetes at the phylum level may have implications in modulation 
of intestinal inflammation. Our gut microbiota transfer experiments 
demonstrated that EP4-modified commensal microbes efficiently 
suppressed intestinal Tregs and mediated intestinal inflammation. 
Furthermore, our findings on the manipulation of gut microbiota 
in mice are in keeping with observations in humans showing 
that ingestion of antipyretic analgesics (i.e., NSAIDs or paracetamol 
that also can inhibit PG synthesis) increased the abundance of 
beneficial gut commensals such as Verrucomicrobia and SCFA- 
producing bacteria such as Butyrivibrio and Clostridiaceae (35). A 
recent report on in vitro culture of commensal bacteria suggested 
that most NSAIDs, including indomethacin and aspirin, were un-
likely to affect bacterial growth on various microbial strains (51). 
PGE2 was reported to promote the growth of some bacterial strains 
such as Escherichia coli (52). Therefore, further studies are needed 
to decipher whether PGE2 acts directly on the gut microbiota or 
indirectly on host cells to regulate the growth, survival, or function 
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Another possible mechanism for EP4 suppression of colonic 
Tregs is through a direct action on MNPs. Manipulation of PGE2-
EP4 signaling (i.e., using COX inhibitors or EP4 agonist) alters the 
numbers of intestinal CD11c+CD11b+MHC II+ MNPs, and deple-
tion of CD11b+ MNPs prevented PGE2-dependent regulation of 
intestinal Tregs. CCR2-expressing monocyte-derived MNPs are crit-
ical for intestinal TH17 cell responses (53), but these migratory 
MNPs are unlikely to be involved in PGE2-dependent regulation of 
intestinal Treg responses, indicating a role for gut resident MNPs. 
Notably, deletion of EP4 in CD11c+ MNPs increased accumulation 
of colonic Tregs, especially the RORt+ subset, indicating an essential 
role for EP4 signaling in MNPs. Thus, PGE2-modified gut microbi-
ota controls MNP production of type I IFNs, which in turn medi-
ates intestinal Tregs and MNPs themselves. This is consistent with a 
recent report showing that gut commensals stimulated CD11b+ 
dendritic cells to produce IFN-, which augmented the prolifera-
tion of intestinal Tregs (46), although IFNAR signaling in Tregs was 
reported to impair Treg suppressive function (54).
PGE2-EP4 signaling more specifically suppresses RORt+ Tregs 
than the RORt− Treg subpopulation. Comparing to RORt−Foxp3+ 
Tregs, RORt+Foxp3+ Tregs express higher levels of mucosal resident 
Treg-associated genes such as Ffar2 (31) that encodes the SCFA re-
ceptor G protein-coupled receptor 43 (GPR43). The SCFA-GPR43 
axis is critical for the development, recruitment, and expansion of 
Fig. 7. Type I IFNs produced by MNPs mediate PGE2 suppression of intestinal Tregs. (A) Gene expression of Ifnb, Irf7, and Isg15 in BMDCs cultured with CMPs that were 
isolated from mice treated with vehicle, indomethacin, or indomethacin plus EP4 agonist. Data shown as means ± SEM of duplicates are representative of two indepen-
dent experiments. a.u., arbitrary units. (B) Gene expression of Ifnb, Irf7, and Isg15 in sorted colonic MNPs from vehicle- or indomethacin-treated mice. Each sample was 
pooled from three to four mice. Data shown as mean gene expression of technical duplicates or triplicates are representative of two independent experiments. (C) Num-
bers of colonic phosphorylated STAT1–positive (pSTAT1+) MNPs and Tregs in mice treated with vehicle or indomethacin (n = 8 each). (D) Percentages and numbers of colon 
LP pSTAT1+Foxp3+ Tregs. (E) Percentages of colon LP CD11c+MHC II+CD11b+ and CD11c+MHC II+CD11b− MNPs in WT and Ifnar−/− mice treated with vehicle, indomethacin, 
or indomethacin plus EP4 agonist (n = 7 to 12). (F) Percentages of colon LP RORt+Foxp3+ Tregs, RORt−Foxp3+ Tregs, and RORt+Foxp3− TH17 cells. Each scatter dot plot 
represents data from one mouse. Data shown as means ± SD are pooled from two (C and D) or four (E and F) independent experiments. Two-tailed unpaired Student’s 
t test (C and D) or ANOVA with Holm-Sidak’s multiple comparisons test (A, E, and F). *P < 0.05, **P < 0.01, and ****P < 0.0001. n.s., not significant. (G) Diagram illustrating how 
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colonic Tregs (10). IFNAR-sufficient Tregs similarly express greater 
Ffar2 and Rorc genes than IFNAR- deficient Tregs (54). Therefore, 
higher levels of SCFA and type I IFN in the intestine of indomethacin- 
treated mice may enhance the accumulation of GPR43-expressing 
RORt+ Tregs compared to that in the mice that were treated with 
vehicle or indomethacin plus EP4 agonist. This may be, at least par-
tially, responsible for a specific effect of the EP4-IFN axis on RORt+ 
Treg subpopulation.
Overactivation of the PGE2 pathway including PGE2 biosynthe-
sis and its receptor signaling is an outstanding marker under most, 
if not all, human inflammatory conditions such as multiple sclero-
sis, rheumatoid arthritis, IBD, and cancers (14). Together with our 
previous findings (26,  27), results from this current study imply 
PGE2 as a common inflammatory mediator for immune inflamma-
tion by balancing T cell responses, i.e., enhancing Treg but limiting 
effector T cell responses. This is further supported by a recent study 
demonstrating that PGE2 exacerbates tumor necrosis factor (TNF)–
induced inflammatory responses in human intestinal epithelial cells 
from patients with IBD who are resistant to TNF inhibitor therapy 
(55). Moreover, studies from multiple groups including ourselves 
have shown that lack of PGE2-EP4 signaling in T cells reduced both 
chemical-triggered acute and naïve T cell transfer–induced chronic 
intestinal inflammation, associated with reduction of inflammatory 
TH1 and/or TH17 cell responses (27, 56). Thus, PGE2 mediates in-
testinal inflammation possibly through actions on both adaptive 
T cells and innate MNPs, and at least in the latter scenario, the gut 
microbiota is involved.
Collectively, we have defined a role for PGE2 in control of intes-
tinal Treg accumulation, which involves MNPs and the gut microbi-
ota, leading to facilitation of mucosal inflammation. Our findings 
provide an explanation for human genetic findings of the association 
between PTGER4 (EP4) gene polymorphisms and IBD susceptibility 
and suggest a potential therapeutic strategy for treating intestinal in-
flammation by targeting the PGE2-EP4-microbiota-MNP-Treg cascade.
MATERIALS AND METHODS
Mice
Rag1−/−, MyD88−/−TRIF−/−, Ifnar−/−, CD11b-DTR, Ccr2−/−, LckCreEP4fl/fl, 
and WT C57BL/6 mice were bred and maintained under specific 
pathogen-free conditions in accredited animal facilities at the Uni-
versity of Edinburgh. To generate MNP-specific EP4-deficient 
mice, we crossed EP4-floxed mice to CD11c-Cre-GFP mice (JAX 
007567). WT mice were bred in our own animal facilities or pur-
chased from Harlan, UK. Age (>7 weeks old) and sex-matched mice 
were used. Mice were randomly allocated into different groups and 
analyzed individually. No mice were excluded from the analysis 
except exclusions due to technical errors in preparation of intestinal 
LP leukocytes. All experiments were conducted in accordance with 
the U.K. Animals (Scientific Procedures) Act of 1986 with local eth-
ical approval from the University of Edinburgh Animal Welfare 
and Ethical Review Body.
Cecal microbiota transplantation, colitis, and treatments 
with small molecular compounds
Recipient specific pathogen–free (SPF) WT C57BL/6 mice were 
pretreated with antibiotics for 2 weeks and rest for 1 day before re-
ceiving fresh cecal microbiota collected from SPF WT C57BL/6 
mice that had been treated with vehicle, indomethacin (5 mg/kg per 
day in drinking water), or indomethacin plus EP4 agonist L-902,688 
(10 g per mouse per day via daily intraperitoneal injection) for 
5 days. After antibiotics treatment, some recipient mice were given 
normal drinking water for another 9 days before euthanasia for 
analysis of colon immune cells in the steady state, while other recip-
ient mice were administered with normal drinking water for 7 days, 
followed by 2.5% (w/v) of DSS (molecular weight, 36 to 50 kDa; MP 
Biochemicals) in drinking water for six consecutive days to induce 
colonic inflammation. The DAI was scored by the following system: 
body weight, 0 (no or <1% weight loss compared to day 0 body 
weight), 1 (1 to 5% weight loss), 2 (5 to 10% weight loss), 3 (10 to 
20% weight loss), and 4 (>20% weight loss); bleeding, 0 (no bleed-
ing), 1 (blood present in/on feces), 2 (visible blood in rectum), and 
4 (visible blood on fur); stool consistency, 0 (well-formed/normal 
stool), 1 (pasty/semiformed stool), 2 (pasty stool with some blood), 
3 (diarrhea that does not adhere to anus), and 4 (diarrhea that does 
adhere to anus); general appearance, 0 (normal), 1 (piloerection 
only), 2 (piloerection and lethargy), and 4 (atoxic, motionless and 
sunken eyes). Mice were immediately culled when body weight loss 
was greater than 25% or the total colitis score is 12 or higher. Indo-
methacin (5 mg/kg per day or indicated doses) and vehicle (0.5% 
EtOH) were administrated through drinking water that was refreshed 
every 2 to 3 days. Butaprost (10 g per injection; Abcam), L-902,688 
(10 g per injection; Cayman Chemical), and control (0.5% EtOH 
in PBS) were used by daily intraperitoneal injections. Antibiotics 
(containing ampicillin, gentamycin, metronidazole, neomycin, and 
vancomycin, each 0.5 mg/ml) and sucralose (4 mg/ml) were used in 
drinking water. DT (25 ng/g of bogy weight; Sigma-Aldrich) was 
injected intraperitoneally every 48 hours.
Histology
Intestine samples were fixed with 10% neutral buffered formalin 
solution (Sigma-Aldrich) and embedded in paraffin, and 5-m 
sections were used for staining with hematoxylin and eosin.
Isolation and staining of intestinal LP leukocytes
Intestinal LP cells were isolated as described previously (19). For 
surface staining, cells were first stained with the Fixable Viability 
Dye eFluor 780 (eBioscience) on ice for 30 min. After wash, cells 
were stained on ice for another 30 min with anti-CD45 (clone 30-F11), 
anti-CD3e (clone 145-2C11), anti-CD4 (clone GK1.5), anti-CD25 
(clone PC61.5), anti-CD11c (clone N418), anti-CD11b (clone M1/70), 
anti-B220 (clone RA3-6B2), and anti-mouse I-A/I-E antibody 
(clone M5/114.15.2). For staining of transcription factors, cells were 
fixed in the Foxp3/Transcription Factor Fix Buffer (eBioscience) for 
2 hours or overnight, followed by staining with anti-mouse Foxp3 
(clone FJK-16s), anti-mouse RORt (clone B2D), anti-mouse 
Helios (clone 22F6), and mouse anti-Stat1 (pY701) (clone 4a) for 
at least 1 hour. All antibodies were purchased from eBioscience, 
BioLegend, or BD Biosciences. Flow cytometry was performed 
on the BD LSRFortessa (BD Biosciences) and analyzed by FlowJo 
software (Tree Star).
BMDC differentiation and stimulation
Bone marrow cells from femurs were cultured at 4 × 105 cells/ml of 
culture medium with granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (20 ng/ml) in complete RPMI 1640 to induce the 
differentiation of BMDCs. RPMI 1640 with GM-CSF was refreshed 
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nonadherent cells after gently swirling the plate and restimulated 
for 6 hours with RPMI 1640 alone or cecal microbial products 
(CMPs) obtained from mice that received various treatments as in-
dicated in related figure legends. CMPs were prepared by dissolving 
cecal contents with sterile PBS (100 mg/ml) with vigorous vertex 
followed by centrifugation at 10,000 rpm for 2 min and filtered 
through a 0.22-m Millex-GP filter unit. The CMP solution was then 
stored at −20°C and diluted by 40 times using PBS(−) for use in 
experiments. Cells were cultured at 37°C with 5% CO2.
Oxylipin analysis
Small intestine and colon samples were weighed and homogenized 
with ceramic beads in 1 ml of antioxidation buffer containing 100 M 
diethylenetriamine pentaacetic acid and 100 M butylated hydro-
xytoluene in PBS using a Bead Ruptor Elite for 2 × 30 s intervals at 
6 m/s, under cooled nitrogen gas (4°C). Samples were spiked with 
2.1 to 2.9 ng of PGE2-d4, PGD2-d4, PGF2-d4, and TXB2-d4 stan-
dards (Cayman Chemical) before homogenization. Lipids were 
extracted by adding a 1.25-ml solvent mixture (1 M acetic acid/
isopropanol/hexane; 2:20:30, v/v/v) to 0.5-ml supernatants in a glass 
extraction vial and vortexed for 30 s. A total of 1.25 ml of hexane 
was added to samples, and after vortexing for 30 s, tubes were cen-
trifuged (500g for 5 min at 4°C) to recover lipids in the upper hex-
ane layer (aqueous phase), which was transferred to a clean tube. 
Aqueous samples were reextracted as above by addition of 1.25 ml 
of hexane, and upper layers were combined. Lipid extraction from 
the lower aqueous layer was then completed according to the Bligh 
and Dyer technique using sequential additions of methanol, chloro-
form, and water, and the lower layer was recovered following cen-
trifugation as above and combined with the upper layers from the 
first stage of extraction. Solvent was dried under vacuum, and lipid 
extract was reconstituted in 200 l of high-performance liquid 
chromatography grade methanol. Lipids were separated by liquid 
chromatography using a gradient of 30 to 100% B over 20 min 
(A, water:Mob B 95:5 + 0.1% acetic acid; B, acetonitrile:metha-
nol –80:15 + 0.1% acetic acid) on an Eclipse Plus C18 Column (Agilent) 
and analyzed on a Sciex QTRAP 6500 liquid chromatography–
tandem mass spectrometry system. Source conditions are as follows: 
temperature at 475°C, IS-4500, GS1 60, GS2 60, and CUR 35. Lipids 
were detecting using multiple reaction monitoring with the follow-
ing parent to daughter ion transitions: PGD1 and PGE1 [M-H], 
353.2/317.2; PGD2, 8-iso PGE2, and PGE2 [M-H], 351.2/271.1; PGF2 
[M-H], 353.2/309.2; 6-keto PGF1 [M-H], 369.2/163.1; TXB2 [M-H], 
369.2/169.1; 13,14-dihydro-15-keto-PGE2 [M-H], 351.2/235.1. 
Deuterated internal standards were monitored using parent-to- 
daughter ion transitions of the following: TXB2-d4 [M-H], 373.2/173.1; 
PGE2-d4 and PGD2-d4 [M-H], 355.2/275.1; PGF2-d4 [M-H], 
357.5/313.2. Chromatographic peaks were integrated using Multi-
Quant 3.0.2 software (Sciex). Peaks were only selected when their 
intensity exceeded three times above the baseline noise. The ratio of 
analyte peak areas to internal standard was taken, and lipids were 
quantified using a standard curve made up and run at the same 
time as the samples. Each oxylipin was then standardized per mil-
ligram of colon tissue.
SCFA profiling
The levels of SCFA (acetic acid, propionic acid, butyric acid, valeric 
acid, caproic acid, heptanoic acid, and caprylic acid) and branched 
SCFA (isobutyric acid and isovaleric acid) in cecal contents were 
detected as described previously (57). Briefly, the SCFA and branched 
SCFA (isobutyric acid and isovaleric acid) were extracted from 
acidified slurries three times in total using diethyl ether. Extracts 
were analyzed using gas chromatography (Agilent 7890A) with flame 
ionization detector, as described previously (cite paper above). Each 
of the SCFA was quantified against calibration curves plotted using 
authentic external standards [acetic acid (174.8 mM), propionic 
acid (133.4 mM), butyric acid (107.3 mM), valeric acid (89.2 mM), 
caproic acid (77.4 mM), heptanoic acid (69.8 mM), caprylic acid 
(58.5 mM), isobutyric acid (106.5 mM), and isovaleric acid (86.9 mM) 
all stored in 2 M NaOH and using 2-ethylbutyric acid (73.2 mM) as 
internal standard. Concentration of SCFA in cecal contents were 
calculated as micromoles per gram and normalized to the vehicle 
control group.
Real-time PCR
RNA purification from sorted MNPs was performed using the RNeasy 
Mini Kit (QIAGEN). Complementary DNA (cDNA) was obtained by 
reverse transcription using the High-Capacity cDNA Reverse Tran-
scription Kits (ThermoFisher Scientific). Samples were analyzed by 
real-time PCR with GoTaq qPCR Master Mix (Promega) on the 
Applied Biosystems 7900HT Fast machine. Primers used are as follows: 
Ifna, 5′-GGACTTTGGATTCCCGCAGGAGAAG-3′ (forward) and 
5′-GCTGCATCAGACAGCCTTGCAGGTC-3′ (reverse); Ifnb, 
5′-AACCTCACCTACAGGGCGGACTTCA-3′ (forward) and 
5′-TCCCACGTCAATCTTTCCTCTTGCTTT-3′ (reverse); Irf7, 
5′-CCCCATCTTCGACTTCAGAG-3′ (forward) and 5′-AAG-
GAAGCACTCGATGTCGT-3′ (reverse); Isg15, 5′-TGACTGTGA-
GAGCAAGCAGC-3′ (forward) and 5′-CCCCAGCATCTT-
CACCTTTA-3′ (reverse); glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh), 5′-TGAACGGGAAGCTCACTGG-3′ (forward) and 
5′-TCCACCACCCTGTTGCTGTA-3′ (reverse). Expression was 
normalized to Gapdh and presented as relative expression to the 
control group by the 2–Ct method.
Total bacterial DNA was extracted from cecal contents using the 
QIAamp DNA Stool Mini Kit (QIAGEN) according to the manu-
facturer’s protocol. DNA concentration and quality in the extracts 
were determined by NanoDrop 1000 spectrophotometer (Thermo 
Fisher Scientific). Bacterial groups in cecal samples were measured 
by real-time PCR using GoTaq qPCR Master Mix (Promega) on 
Applied Biosystems 7900HT Fast or StepOne Plus Real-Time PCR 
Systems. Primers used for 16S rRNA gene qPCR are as follows (58–63): 
Firmicutes, 5′-GGAGYATGTGGTTTAATTCGAAGCA-3′ (forward; 
Firm934F) and 5′-AGCTGACGACAACCATGCAC-3′ (reverse; 
Firm1060R); Bacteroidetes, 5′-GGARCATGTGGTTTAATTC-
GATGAT-3′ (forward; Bact934F) and 5′-AGCTGACGACAACCATG-
CAG-3′ (reverse; Bact1060R); Clostridium XIVa, 5′-AAATGACGGTACCT-
GACTAA-3′ (forward) and 5′-CTTTGAGTTTCA TTCTTGCGAA-3′ 
(reverse); Clostridium sp., 5′-CACCAAGGCGACGATCAGT-3′ (forward) 
and 5′-GAGTTTGGGCCGTGTCTCA-3′ (reverse); C. coccoides 
subgroup, 5′-AAATGACGGTACCTGACTAA-3′ (forward) and 
C. coccoides subgroup, 5′-CTTTGAGTTTCATTCTTGCGAA-3′ 
(reverse); C. coccoides–Eubacteria rectale group, 5′-CGGTACCT-
GACTAAGAAGC-3′ (forward) and 5′-AGTTTYATTCTTGCGAACG-3′ 
(reverse); ASF500, 5′-GTCGCATGGCACTGGACATC-3′ (forward; 
500-183F) and 5′-CCTCAGGTACCGTCACTTGCTTC-3′ (reverse; 
500-445R); ASF360, 5′-CTTCGGTGATGACGCTGG-3′ (forward; 360-
81F) and 5′-GCAATAGCCATGCAGCTATTGTTG-3′ (reverse; 360-
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UnivF) and 5′-GACTACCAGGGTATCTAATCCTGTT-3′ (reverse; 
UnivR). Expression was normalized to all bacterial DNA, and relative 
expression levels were calculated relatively to the vehicle control 
group by the 2–Ct method.
16S rRNA gene sequencing
Aliquots for sequencing of the 16S rRNA gene were first amplified 
with the V3-V4 region primers 341F (5′-CCTACGGGAGGCAG-
CAG-3′) and 518R (5′-ATTACCGCGGCTGCTGG-3′) as described 
previously (64). A reagent-only control (DNA extraction kit blank) 
and a mock bacterial community (HM-782D, BEI Resources, 
American Type Culture Collection, Manassas, VA) were also 
prepared in the same manner. A single library pool was com-
piled using equimolar concentrations of DNA as measured using 
a fluorometric assay (Qubit dsDNA Broad-Range Assay Kit, In-
vitrogen, UK). The Illumina MiSeq platform (Illumina, CA) was 
used for sequencing (Edinburgh Genomics, UK), using V2 chemistry 
and producing 250–base pair paired-end reads. Using the mock bac-
terial community data, the sequencing error rate was calculated as 
0.01%. The raw sequence reads, with primers removed, are publicly 
available via the National Center for Biotechnology Information 
Sequence Read Archive under accession number PRJNA564944.
16S rRNA gene sequencing data analysis
For the raw 16S RNA data in FASTQ format, amplicon primers 
were first removed to prevent false-positive detection of chimeras 
using the cutadapt plugin (65). Ten thousand sequences were sam-
pled at random, and the qualities at each base position were exam-
ined for determining the parameters of the denoising process. The 
paired-end reads were further trimmed, filtered, denoised, and 
merged using the DADA2 plugin (66) through the Wales super-
computer portal. A naïve Bayes classifier within QIIME2 v2019.10 
(67) was trained against the Silva v132 database (https://arb-silva.de/) 
on the amplified region. In addition, a machine learning Python 
library scikit-learn (68) was used to classify OTUs on the basis of 
100% sequence identity. A total of seven taxonomic levels were used 
for 16S rRNA datasets. For measuring diversity, we generated de novo 
phylogenetic trees through multiple sequence alignment, masking, 
tree building, and rooting using the multiple alignment using fast 
Fourier transform (MAFFT) program (69). Percent abundance of 
taxa was determined by calculating it as a proportion of the total read 
count across all samples. For instance, the percent abundance of the 
ith taxa in the jth sample is computed as
 f( x i,j ) =  
 R i,j  _   j=1 
n   R i 
 × 100  
where n is the total number of samples and R represents read counts 
of each taxa.
The OTU table was rarefied across samples to the 90% of the 
lowest sample depth with a random seed set as 123 to eliminate the 
bias caused by the different sample sizes. For the overall bacterial 
community within samples, -diversity estimators including the 
observed species, the Chao1 index, the Shannon diversity, and the 
InvSimpson index were calculated using phyloseq (70). The -diversity 
estimates were compared between three groups using nonparametric 
Kruskal-Wallis test along with Dunn’s multiple comparison correc-
tion. -Diversity between samples was computed using the un-
weighted UniFrac distances (71).
Statistical analysis
All data were expressed as means ± SD except that in Fig. 7A, where 
the data were expressed as means ± SEM as indicated in the figure 
legends. Statistical significance between two groups was examined 
by unpaired Student’s t test, while the analysis of variance (ANOVA) 
with post hoc Holm-Sidak’s multiple comparisons test was used 
to evaluate multiple groups. Statistical work was performed using 
Prism 8 software (GraphPad), and P < 0.05 was considered as 
significance.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/7/eabd7954/DC1
View/request a protocol for this paper from Bio-protocol.
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